EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P21
Within normal range
vs 3Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | -1.50% |
| 2024 | 1.35% |
| 2023 | -14.15% |
| 2022 | 13.65% |
| 2021 | 15.34% |
| 2020 | -3.55% |
| 2019 | 265.41% |
| 2018 | 16.22% |
| 2017 | 24.65% |
| 2016 | 11.88% |